Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.
Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, Verheul HM, Serné EH, Lammertsma AA, Smit EF.
Van der Veldt AA, et al. Among authors: postmus pe.
Cancer Cell. 2012 Jan 17;21(1):82-91. doi: 10.1016/j.ccr.2011.11.023.
Cancer Cell. 2012.
PMID: 22264790
Free article.
Clinical Trial.